Last reviewed 2026-04-19 · How we verify

DIPERODON

Phase 2 active Small molecule

DIPERODON is a diperodon drug. It is currently in Phase 2 development.

Diperodon works by blocking sodium channels in the brain to reduce abnormal electrical activity.

Diperodon is a small molecule drug that targets sodium channel alpha subunits in the brain, specifically types I, II, and III. It is classified as a diperodon, but its commercial status and approved indications are unknown. As a small molecule, diperodon works by interacting with specific proteins in the brain to modulate sodium channel activity. The exact mechanism of action and key safety considerations are not well-documented. Further research is needed to fully understand the potential benefits and risks of this drug.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DIPERODON
Drug class	diperodon
Target	Sodium channel alpha subunits; brain (Types I, II, III)
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain cells are like a row of houses with electrical wires. Sodium channels are like the electrical outlets that let electricity flow in and out of the houses. Diperodon blocks these outlets, reducing the flow of electricity and helping to calm down abnormal electrical activity in the brain.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DIPERODON CI brief — competitive landscape report
DIPERODON updates RSS · CI watch RSS

Frequently asked questions about DIPERODON

What is DIPERODON?

DIPERODON is a diperodon drug.

How does DIPERODON work?

Diperodon works by blocking sodium channels in the brain to reduce abnormal electrical activity.

What drug class is DIPERODON in?

DIPERODON belongs to the diperodon class. See all diperodon drugs at /class/diperodon.

What development phase is DIPERODON in?

DIPERODON is in Phase 2.

What does DIPERODON target?

DIPERODON targets Sodium channel alpha subunits; brain (Types I, II, III) and is a diperodon.

Drug class: All diperodon drugs
Target: All drugs targeting Sodium channel alpha subunits; brain (Types I, II, III)
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing